Shareholders meeting

Date: 31st July, 2026 Listing Department, National Stock Exchange of India Limited Exchange Plaza, Plot No C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400051 NSE Symbol: BALAXI Subject: Notice of 83rd Annual General Meeting (‘AGM’) Dear Sir / Madam, Pursuant to Regulation 30 and Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘Listing Regulations’), please find enclosed the Notice convening the 83rd AGM of the Company scheduled to be held on Monday, 24th August, 2026 at 11:00 A.M. (IST) through Video Conferencing / Other Audio Visual Means (‘VC/OAVM’) in compliance with the circulars issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India in this regard. Detailed instructions for remote e-voting, participation in the AGM through VC/OAVM mode and e-voting at the AGM are provided in the Notice of the AGM. Pursuant to Regulation 36 of the Listing Regulations, the Annual Report for FY 2025-26 including Business Responsibility and Sustainability Report and Notice of AGM is being sent electronically to the shareholders who have registered their email IDs with the Company or Depository Participant(s) or Registrar and Share Transfer Agent of the Company. Further, a letter providing the web-link to access the Annual Report is being sent to those Members who have not registered their e-mail address. Pursuant to Regulation 46 of the Listing Regulations, the said Annual Report and Notice of the 83rd AGM are available on the Company’s website at: Annual Report for FY 2025-26: https://balaxipharma.in/assets/images/articles/Balaxi_Annual_Report_2025-26.pdf Notice of the 83rd AGM: https://balaxipharma.in/assets/images/articles/Balaxi_83rd_AGM_Notice_to_be_held_on_24th_Augu st_2026.pdf This is for your information and record. Thanking You. Yours faithfully, For Balaxi Pharmaceuticals Limited Aman Purohit (Company Secretary & Compliance Officer) ICSI Membership No.: A59345 (Encl: As above) Notice (contd.) BALAXI PHARMACEUTICALS LIMITED CIN: L25191TG1942PLC121598 Registered Office: Plot No. 409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase – III, Road No. 81, Jubilee Hills, Hyderabad, Telangana – 500096, India. Phone: +91 40 2355 5300 Email: secretarial@balaxi.in Website: www.balaxipharma.in Notice of the 83rd Annual General Meeting Notice is hereby given that the 83rd Annual General Meeting To consider and, if thought fit, to pass the following resolution (“AGM”) of the Members of Balaxi Pharmaceuticals Limited as a Special Resolution: (“the Company”) will be held on Monday, 24th August, 2026 “RESOLVED THAT pursuant to the provisions of Sections at 11:00 AM (IST) through Video Conferencing (“VC”) / Other 149, 150, 152 read with Schedule IV and other applicable Audio-Visual Means (“OAVM”) to transact the following provisions of the Companies Act, 2013 (‘Act’) (including business: any statutory modification(s) or re-enactment(s) thereof for ORDINARY BUSINESS: the time being in force), the Companies (Appointment and Qualification of Directors), Rules, 2014, and Regulations Item No. 1 – Adoption of Audited Standalone Financial 17, 25 and any other applicable provisions of Securities and Statements: Exchange Board of India (Listing Obligations and Disclosure To receive, consider and adopt the Audited Standalone Requirements) Regulations, 2015, (‘SEBI Listing Regulations’) Financial Statements of the Company for the financial year as amended from time to time, and the Articles of Association ended March 31, 2026, and the reports of the Board of of the Company, Ms. Akshita Ostwal (DIN: 10026552), who Directors and the Auditors thereon and in this regard, to was appointed as an Independent Director of the Company consider and if thought fit, to pass the following resolution as by the members by way of Postal Ballot passed on 06th an Ordinary Resolution: November, 2024; and who holds office up to September 04, 2026 and who is eligible for being re-appointed as an “RESOLVED THAT the Audited Standalone Financial Independent Director of the Company and in respect of whom Statements of the Company for the financial year ended the Company has received a Notice in writing from a Member March 31, 2026, and the reports of the Board of Directors under Section 160 of the Act proposing his candidature and Auditors thereon, as circulated to the Members, be and for the office of Director, on the recommendation of the are hereby considered and adopted.” Nomination and Remuneration Committee and the Board of Item No. 2 – Adoption of Audited Consolidated Financial Directors at their meeting held on 28th May, 2026; be and Statements: is hereby reappointed as an Independent Director of the Company, not liable to retire by rotation, to hold office for a To receive, consider and adopt the Audited Consolidated second term of 5 (Five) consecutive years commencing from Financial Statements of the Company for the financial year 05th September, 2026 to 04th September, 2031. ended March 31, 2026, and the report of the Auditors thereon and in this regard, to consider and if thought fit, to RESOLVED FURTHER THAT the directors and the Company pass the following resolution as an Ordinary Resolution: Secretary and Compliance Officer of the Company be and are hereby severally authorised to do all such acts, deeds, “RESOLVED THAT the Audited Consolidated Financial matters and things as may be considered necessary, desirable, Statements of the Company for the financial year ended or expedient to give effect to this Resolution.” March 31, 2026, and the report of the Auditors thereon, as circulated to the Members, be and are hereby considered and adopted.” By Order of the Board of Directors For Balaxi Pharmaceuticals Limited Item No. 3 – Re-appointment of Mrs. Minoshi Maheshwari (DIN: 01575975) as a Director, liable to retire by rotation: Aman Purohit To appoint a Director in place of Mrs. Minoshi Maheshwari (Company Secretary and Compliance Officer) (DIN: 01575975), who retires by rotation and being eligible, Membership No.: A59345 seeks re-appointment, and in this regard, to consider and if Date: 28th May, 2026 thought fit, to pass the following resolution as an Ordinary Place: Hyderabad Resolution: Registered Office: Plot No. 409, “RESOLVED THAT pursuant to the provisions of Section H. No. 8-2-293, Maps Towers, 152 and other applicable provisions, if any, of the Companies 3rd Floor, Phase – III, Road No. 81, Act, 2013, Mrs. Minoshi Maheshwari (DIN: 01575975), who Jubilee Hills, Hyderabad Telangana– 500096, India. retires by rotation at this meeting and being eligible offers CIN: L25191TG1942PLC121598 herself for re-appointment, be and is hereby re-appointed as Website: www.balaxipharma.in a Director of the Company.” Email: secretarial@balaxi.in SPECIAL BUSINESS: Telephone: +91 40 23555300 Item No. 4 – Re-appointment of Ms. Akshita Ostwal (DIN: 10026552), as an Independent Director of the Company: Notice (contd.) Balaxi Pharmaceuticals Limited Notes: for participation at the AGM through VC/ OAVM will be made available for 1000 members on first 1. The Ministry of Corporate Affairs (“MCA”) has, vide come first serve basis. This will not include large its General Circular dated September 22, 2025 read Shareholders (Shareholders holding more than 2% or together with circulars dated April 8, 2020, April 13, more shareholding), Promoters, Institutional Investors, 2020, May 5, 2020, January 13, 2021, December 8, Directors, Key Managerial Personnel, the Chairpersons 2021, December 14, 2021, May 5, 2022, December of the Audit Committee, Nomination and Remuneration 28, 2022, September 25, 2023 and September 19, Committee and Stakeholders Relationship Committee, 2024 (collectively referred to as “MCA Circulars”), Auditors etc. who are allowed to attend the AGM permitted convening the Annual General Meeting without restriction on account of first come first served (“AGM” / “Meeting”) through Video Conferencing basis. (“VC”) [Showing first 8,000 characters — download PDF for full document]